昂利康(002940.SZ):磷酸西格列汀片獲得藥品註冊證書、碳酸鑭獲得化學原料藥上市申請批准通知書
格隆匯7月1日丨昂利康(002940.SZ)公佈,近日,浙江昂利康製藥股份有限公司收到國家藥品監督管理局簽發的磷酸西格列汀片(25mg、50mg、100mg)《藥品註冊證書》及碳酸鑭原料藥《化學原料藥上市申請批准通知書》。
磷酸西格列汀片最早由MerckSharp&Dohme公司研發,於2006年10月首次在美國上市,2009年9月批准進口。磷酸西格列汀是一種強效、高選擇性二肽基肽酶-4(DPP-4)抑制劑,用於改善2型糖尿病患者的血糖控制。
碳酸鑭用於治療高磷血癥。碳酸鑭作為磷結合劑的活性取決於鑭離子與磷酸鹽的高親和性,鑭離子在胃內酸性環境中從碳酸鹽中釋放出來,與食物中的磷結合,形成不溶性磷酸鑭,因而降低了胃腸道對磷的吸收。公司於2022年11月獲得碳酸鑭原料藥受理通知書,並於近日獲得國家藥監局批准。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.